Discovery of pyrroloaminopyrazoles as novel PAK inhibitors
The P21-activated kinases (PAK) are emerging antitumor therapeutic targets. In this paper, we describe the discovery of potent PAK inhibitors guided by structure-based drug design. In addition, the efflux of the pyrrolopyrazole series was effectively reduced by applying multiple medicinal chemistry strategies, leading to a series of PAK inhibitors that are orally active in inhibiting tumor growth in vivo.
Guo, Chuangxing,McAlpine, Indrawan,Zhang, Junhu,Knighton, Daniel D.,Kephart, Susan,Johnson, M. Catherine,Li, Haitao,Bouzida, Djamal,Yang, Anle,Dong, Liming,Marakovits, Joseph,Tikhe, Jayashree,Richardson, Paul,Guo, Lisa C.,Kania, Robert,Edwards, Martin P.,Kraynov, Eugenia,Christensen, James,Piraino, Joseph,Lee, Joseph,Dagostino, Eleanor,Del-Carmen, Christine,Deng, Ya-Li,Smeal, Tod,Murray, Brion W.
p. 4728 - 4739
(2012/07/28)
More Articles about upstream products of 1375799-72-6
Get Best Price for1375799-72-6(S)-2-(dimethylamino)-1-phenylethyl 6,6-dimethyl-3-(1-(trifluoromethyl)cyclobutanecarboxamido)-4,6 dihydropyrrolo[3,4-c]pyrazole-5(1H)-carboxylate